Cardiff Oncology (NASDAQ:CRDF) Now Covered by Analysts at Craig Hallum

Craig Hallum initiated coverage on shares of Cardiff Oncology (NASDAQ:CRDF) in a research report released on Friday morning, MarketBeat Ratings reports. The firm issued a buy rating and a $8.00 price target on the stock.

Cardiff Oncology Trading Up 9.5 %

Shares of CRDF stock opened at $2.31 on Friday. The firm has a fifty day simple moving average of $2.30 and a 200-day simple moving average of $3.30. The company has a market capitalization of $103.31 million, a PE ratio of -2.57 and a beta of 1.95. Cardiff Oncology has a twelve month low of $0.94 and a twelve month high of $6.42.

Cardiff Oncology (NASDAQ:CRDF) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.01). The firm had revenue of $0.16 million during the quarter, compared to analyst estimates of $0.12 million. Cardiff Oncology had a negative return on equity of 62.65% and a negative net margin of 6,143.91%. During the same quarter in the prior year, the firm earned ($0.25) EPS. Equities research analysts predict that Cardiff Oncology will post -1 EPS for the current year.

Hedge Funds Weigh In On Cardiff Oncology

Institutional investors have recently made changes to their positions in the business. Dimensional Fund Advisors LP grew its position in shares of Cardiff Oncology by 34.4% during the second quarter. Dimensional Fund Advisors LP now owns 19,098 shares of the company’s stock worth $42,000 after buying an additional 4,892 shares in the last quarter. Vanguard Group Inc. grew its holdings in Cardiff Oncology by 0.5% during the 1st quarter. Vanguard Group Inc. now owns 1,921,257 shares of the company’s stock worth $10,260,000 after acquiring an additional 9,468 shares in the last quarter. Callan Capital LLC increased its position in shares of Cardiff Oncology by 37.2% in the 1st quarter. Callan Capital LLC now owns 42,747 shares of the company’s stock worth $228,000 after purchasing an additional 11,600 shares during the last quarter. Point72 DIFC Ltd bought a new stake in shares of Cardiff Oncology in the 2nd quarter worth about $27,000. Finally, Ground Swell Capital LLC acquired a new stake in shares of Cardiff Oncology in the 2nd quarter valued at about $38,000. 16.29% of the stock is owned by institutional investors and hedge funds.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.